[go: up one dir, main page]

PE20070099A1 - N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso - Google Patents

N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso

Info

Publication number
PE20070099A1
PE20070099A1 PE2006000759A PE2006000759A PE20070099A1 PE 20070099 A1 PE20070099 A1 PE 20070099A1 PE 2006000759 A PE2006000759 A PE 2006000759A PE 2006000759 A PE2006000759 A PE 2006000759A PE 20070099 A1 PE20070099 A1 PE 20070099A1
Authority
PE
Peru
Prior art keywords
phenyl
acid amide
heteroarylpiperazinyl
fatty acid
piperazin
Prior art date
Application number
PE2006000759A
Other languages
English (en)
Inventor
Richard Apodaca
J Guy Breitenbucher
Mark Seirstad
Wei Xiao
Kanaka Pattabiraman
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20070099A1 publication Critical patent/PE20070099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

REFERIDA A UN COMPUESTO DE N-HETEROARILPIPERAZINIL UREA DE FORMULA (I), DONDE Ar1 ES PIRIDILO, TIAZOLILO, OXAZOLILO, NAFTILO, ENTRE OTROS; R2 ES R3, R4 O Ar2; R3 ES N-PIPERIDINILO, N-PIPERAZINILO, N-MORFOLINILO, ENTRE OTROS; R4 ES -NReRf; Re Y Rf SON H, ALQUILO C1-C4, CICLOALQUILO C3-C7; Ar2 ES FENILO, TIOFENILO, PIRIDILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (2-CLORO-FENIL)-AMIDA DE ACIDO 4-(3-FENIL-[1,2,4]TIADIAZOL-5-IL)-PIPERAZIN-1-CARBOXILICO, (3-FLUOR-FENIL)-AMIDA DE ACIDO 4-(3-FENIL-[1,2,4]TIADIAZOL-5IL)-PIPERAZIN-1-CARBOXILICO, (4-FLUOR-FENIL)-AMIDA DE ACIDO 4-(3-FENIL-[1,2,4]TIADIAZOL-5-IL)-PIPERAZIN-1-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA AMIDA HIDROLASA DEL ACIDO GRASO (FAAH) Y SON UTILES EN ELE TRATAMIENTO DE LA ANSIEDAD, DOLOR, INFLAMACION, TRASTORNOS DEL SUENO, ENTRE OTROS
PE2006000759A 2005-06-30 2006-06-28 N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso PE20070099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69616605P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
PE20070099A1 true PE20070099A1 (es) 2007-02-06

Family

ID=37075785

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000759A PE20070099A1 (es) 2005-06-30 2006-06-28 N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso

Country Status (5)

Country Link
US (1) US7541359B2 (es)
AR (1) AR056404A1 (es)
PE (1) PE20070099A1 (es)
TW (1) TW200740801A (es)
WO (1) WO2007005510A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
US20070123572A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
SI2937341T1 (sl) 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
CA2665804A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
US20090099240A1 (en) * 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
MX2009004233A (es) * 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
WO2008153752A2 (en) * 2007-05-25 2008-12-18 Janssen Pharmaceutica N.V. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2009105220A1 (en) * 2008-02-19 2009-08-27 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
TWI434842B (zh) 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
BRPI0923819B1 (pt) * 2008-12-24 2021-11-09 Bial-Portela & Ca, S.A. Compostos inibidores de hidrolase amida de ácidos graxos, composições e usos dos mesmos
WO2010120935A1 (en) * 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
RS53856B1 (sr) * 2009-06-11 2015-08-31 Abbvie Bahamas Ltd. Heterociklična jedinjenja kao inhibitori hepatitis c virusa
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
BR112012013801A2 (pt) * 2009-12-11 2019-09-24 Du Pont composto,método para inibir a atividade de hidrolase de amida de ácido graxo em um indivíduo,composição farmacêutica e método para tratar um individuo com dor
US20130029978A1 (en) 2009-12-25 2013-01-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
JP5715646B2 (ja) * 2010-01-07 2015-05-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ 殺菌・殺カビ性ヘテロ環式化合物
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103619825B (zh) * 2011-07-01 2015-10-14 瑞敏德股份有限公司 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物
CA2841037C (en) 2011-08-17 2020-03-31 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
CA3002676A1 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
TWI770104B (zh) 2017-01-11 2022-07-11 美商羅登醫療公司 組蛋白去乙醯酶雙環抑制劑
PL3664802T3 (pl) 2017-08-07 2022-07-11 Alkermes, Inc. Bicykliczne inhibitory deacetylaz histonowych
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
US12410137B2 (en) 2023-07-17 2025-09-09 Apogee Pharmaceuticals, Inc. Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5347725Y2 (es) 1971-06-18 1978-11-15
US5612380A (en) 1994-09-27 1997-03-18 The Scripps Research Institute Method for sleep induction
CZ288002B6 (cs) 1995-01-11 2001-03-14 Samjin Pharmaceutical Co., Ltd. Piperazinové deriváty a farmaceutický prostředek s protinádorovou aktivitou je obsahující
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JP3476203B2 (ja) 1997-02-24 2003-12-10 ザイモジュネティックス インコーポレイテッド カルシトニン擬似体
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
CA2501575A1 (en) 2002-10-08 2004-04-22 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Ｃｏｘ−２及びｆａａｈ阻害剤
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
AR051026A1 (es) * 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
SI2937341T1 (sl) 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
ES2433290T3 (es) 2005-02-17 2013-12-10 Astellas Pharma Inc. Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor

Also Published As

Publication number Publication date
TW200740801A (en) 2007-11-01
US20070004741A1 (en) 2007-01-04
AR056404A1 (es) 2007-10-10
US7541359B2 (en) 2009-06-02
WO2007005510A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
PE20070099A1 (es) N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
PE20061114A1 (es) Piperazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
PE20081265A1 (es) Compuestos de biaril eter urea como inhibidores de faah
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20090547A1 (es) DERIVADOS DE PIRAZINONA COMO INHIBIDORES DE p38 QUINASA
PE20080714A1 (es) DERIVADOS HETEROCICLICOS COMO MODULADORES DE LA ACTIVIDAD DE LA ESTEARIL-CoA-DESATURASA
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
AR035631A1 (es) Compuestos quimicos
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
DK0738262T3 (da) Hidtil ukendte heterocykliske forbindelser
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
PE20041080A1 (es) Preparacion de medicamentos derivados de indolina sustituidos con heterociclos
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200700061A (en) Organic compounds
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine
PE20121439A1 (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
PE20091079A1 (es) Compuestos heterociclicos como moduladores npy y2
UY25888A1 (es) Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PE20071034A1 (es) Compuestos heterociclicos como inhibidores de cetp

Legal Events

Date Code Title Description
FA Abandonment or withdrawal